BeiGene, Ltd. (BGNE)

134.82 -1.46 (-1.07%) At close: 04:00PM EDT

BeiGene, Ltd.

55 Cambridge Parkway
Suite 700W
Cambridge, MA 02142
United States
781-801-1800
https://www.beigene.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8,300

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. John V. Oyler	Co-Founder, Exec. Chairman & CEO	1.75M	N/A	1968
Dr. Xiaobin Wu Ph.D.	Pres, COO & GM of China	1.64M	N/A	1962
Dr. Xiaodong Wang Ph.D.	Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director	250k	N/A	1963
Ms. Julia Wang	CFO & Principal Accounting Officer	798.14k	N/A	1971
Mr. Wang Lai	Global Head of R&D	1.13M	20.81M	1977
Dr. Edna Huang M.D.	Consultant	768.08k	9.35M	1973
Mr. Daniel Maller	VP of Fin. & Accounting	N/A	N/A	N/A
Ms. Mi Zhou	Sr. Director of Investor Relations	N/A	N/A	N/A
Mr. Kevin C. Mannix	Sr. VP of Investor Relations.	N/A	N/A	N/A
Ms. Diana Lee Francis	VP and Global Head of Quality & Regulatory Compliance	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

BeiGene, Ltd.’s ISS Governance QualityScore as of July 1, 2022 is 6. The pillar scores are Audit: 7; Board: 4; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.